Combined antihypertensive and lipid-Lowering treatment

Current Hypertension Reports

Volumn 6, Issue 4, 2004, Pages 300-306

  Cesari, Maurizio ^a   Pessina, Achille C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISRADIPINE; LACIDIPINE; LOSARTAN; MEVINOLIN; NIFEDIPINE; NITRIC OXIDE SYNTHASE; PRAVASTATIN; SIMVASTATIN; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG POTENTIATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; NONHUMAN; PREVALENCE; PRIMARY PREVENTION; SECONDARY PREVENTION; VASCULAR ENDOTHELIUM;

EID: 4344714594     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-004-0025-5     Document Type: Article

References (59)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
2. De Backer G, Ambrosioni E, Borch-Johnsen K, et al.: European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003, 24:1601-1610.
3. Kannel WB: Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000, 13:3S-10S.
4. 3 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003, 21:1011-1053.
5. 9 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999, 17:151-183.
6. Conroy RM, Pyorala K, Fitzgerald AP, et al.: Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003, 24:987-1003.
7. Kannel WB: Contributions of the Framingham Study to the conquest of coronary artery disease. Am J Cardiol 1988, 62:1109-1112.
8. Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
9. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615-1622.
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
11. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996, 335:1001-1009.
12. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998, 339:1349-1357.
13. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
14. U.S. Department of Health and Human Services (DHHS): National Centre for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-1994. NHANES III Examination Data File (CD ROM). Public Use Data File Documentation Number 76200. Hyattsville, MD: Centers for Disease Control and Prevention; 1996.
15. Sueta CA, Chowdhury M, Boccuzzi SJ, et al.: Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999, 83:1303-1307.
16. Kristianson K, Fyhrquist F, Devereux RB, et al.: An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension LIFE Study. Clin Ther 2003, 25:1186-1199.
17. Cesari M, Maiolino G, Colonna S, et al.: Undertreatment with lipid-lowering drugs of high-risk coronary heart disease patients of the GENICA study. J Cardiovasc Pharmacol 2003, 42:484-490.
18. Sever PS, Dahlof B, Poulter NR, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
19. Hebert PR, Gaziano JM, Chan KS, Hennekens CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997, 278:313-321.
20. Wolf-Maier K, Cooper RS, Kramer H, et al.: Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004, 43:10-17.
21. Neaton JD, Wentworth D: Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992, 152:56-64.
22. Thomas F, Bean K, Guize L, et al.: Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. Eur Heart J 2002, 23:528-535.
23. Sueta CA, Chowdhury M, Boccuzzi SJ, et al.: Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999, 83:1303-1307.
24. Pearson TA, Laurora I, Chu H, Kafonek S: The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000, 160:459-467.
25. Hulley S, Grady D, Bush T, et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998, 280:605-613.
26. Byington RP, Davis BR, Plehn JF, et al.: Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 2001, 103:387-392.
27. Maron DJ, Fazio S, Linton MF: Current perspectives on statins Circulation 2000, 101:207-213.
28. Waters D, Higginson L, Gladstone P, et al.: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994, 89:959-968.
29. Jukema JW, Bruschke AV, van Boven AJ, et al.: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995, 91:2528-2540.
30. Mondillo S, Ballo P, Barbati R, et al.: Effects of sinavastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 2003, 114:359-364.
31. Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998, 279:1643-1650.
32. Yang Z, Kozai T, van der LB, et al.: HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Coll Cardiol 2000, 36:1691-1697.
33. Wassmann S, Laufs U, Muller K, et al.: Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002, 22:300-305.
34. Kawashima S, Yamashita T, Miwa Y, et al.: HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke 2003, 34:157-163.
35. Yamashita T, Kawashima S, Miwa Y, et al.: A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats. J Hypertens 2002, 20:2465-2473.
36. Hasegawa H, Yamamoto R, Takano H, et al.: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol 2003, 35:953-960.
37. O'Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997, 95:1126-1131.
38. Egashira K, Hirooka Y, Kai H, et al.: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994, 89:2519-2524.
39. Glorioso N, Troffa C, Filigheddu F, et al.: Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999, 34:1281-1286.
40. Sposito AC, Mansur AP, Coelho OR, et al.: Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999, 83:1497-1499, A8.
41. Ferrier KE, Muhlmann MH, Baguet JP, et al.: Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002, 39:1020-1025.
42. Vasa M, Fichtlscherer S, Adler K, et al.: Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001, 103:2885-2890.
43. Orekhov AN, Tertov VV, Sobenin IA, et al.: Antiatherosclerotic and antiatherogenic effects of a calcium antagonist plus statin combination: amlodipine and lovastatin. Int J Cardiol 1997, 62(Suppl 2):S67-S77.
44. van de Poll SW, Delsing DJ, Jukema JW, et al.: Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice. J Mol Cell Cardiol 2003, 35:109-118.
45. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin on Recovery of Coronary Endothelial Function). Circulation 2003, 107:422-428.
46. Jukema JW, Zwinderman AH, van Boven AJ, et al.: Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group. Arterioscler Thromb Vasc Biol 1996, 16:425-430.
47. Borghi C, Prandin MG, Costa FV, et al.: Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000, 35:549-555.
48. Samuelsson O, Wilhelmsen L, Andersson OK, et al.: Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension: results from the primary prevention trial in Goteborg, Sweden. JAMA 1987, 258:1768-1776.
49. Shepherd J, Blauw GJ, Murphy MB, et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
50. Sacks FM, Tonkin AM, Shepherd J, et al.: Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000, 102:1893-1900.
51. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002, 288:2998-3007.
52. Gotto AM: Lipid management in diabetic patients: lessons from prevention trials. Am J Med 2002, 112(Suppl8A): 19S-26S.
53. Freeman DJ, Norrie J, Sattar N, et al.: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357-362.
54. Etingin OR, Hajjar DP: Calcium channel blockers enhance cholesteryl ester hydrolysis and decrease total cholesterol accumulation in human aortic tissue. Circ Res 1990, 66:185-190.
55. Taddei S, Virdis A, Ghiadoni L, et al.: Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension 2001, 37:943-948.
56. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, et al.: Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet 1990, 335:1109-1113.
57. Borhani NO, Mercuri M, Borhani PA, et al.: Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA 1996, 276:785-791.
58. Zanchetti A, Bond MG, Hennig M, et al.: Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002, 106:2422-2427.
59. Zanchetti A, Rosei EA, Dal Palu C, et al.: The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998, 16:1667-1676.